Page 24 - Research Models News Today

New Hampshire Trust acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 518 shares of the medical research company’s stock, valued at approximately $113,000. A number of other hedge […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $190.39, for a total transaction of $65,684.55. Following the transaction, the executive vice president now owns 24,026 shares in […]

FDx Advisors Inc. reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 16.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,531 shares of the medical research company’s stock after selling 1,934 shares during the […]

CWS Financial Advisors LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,045 shares of the medical research company’s stock, valued at approximately $303,000. Other hedge funds also […]

Bellecapital International Ltd. lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,564 shares of the medical research company’s stock after acquiring an […]

StockNews.com assumed coverage on shares of Charles River Laboratories International (NYSE:CRL – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the medical research company’s stock. A number of other brokerages have also recently commented on CRL. Guggenheim raised Charles River Laboratories International from a […]

Mitchell & Pahl Private Wealth LLC raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 8.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,231 shares of the medical research company’s stock after purchasing an additional […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $190.39, for a total transaction of $65,684.55. Following the sale, the executive vice president now directly owns 24,026 shares […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) – Stock analysts at William Blair reduced their Q4 2023 earnings estimates for Charles River Laboratories International in a research report issued on Friday, May 12th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings of $2.46 per share for […]

Impax Asset Management Group plc purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) during the fourth quarter, HoldingsChannel reports. The firm purchased 2,155 shares of the medical research company’s stock, valued at approximately $470,000. Several other hedge funds and other institutional investors have also bought and sold […]